UMP Healthcare Holdings Ltd

UMP Healthcare Holdings Ltd has a basic and diluted share count of 810,955,244 shares outstanding, indicating no immediate dilution pressure from share issuance. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.

The company reported last actual revenue of 585,630,000 HKD, but no profitability metrics or returns data are available for comparison against industry benchmarks. Without access to margin data or return metrics, it is not possible to evaluate the company's performance relative to its peers in the Investment Management & Fund Operators industry.

There is no detailed breakdown of the company's segments or geographic exposure provided in the available data, making it difficult to assess revenue concentration or diversification. The lack of segmental data also limits the ability to evaluate the company's exposure to different markets or product lines.

The company's growth trajectory is unclear due to the absence of historical revenue data and forward-looking guidance. The reported last actual revenue of 585,630,000 HKD does not provide sufficient context to determine the company's growth rate or future expectations.

The risk assessment indicates a low dilution potential, with no immediate pressure from share issuance or capital raising activities. However, the lack of liquidity data and the absence of going-concern language in the source documents suggest that the company's financial stability and access to capital may be uncertain.

No recent events, such as filings or transcripts, are available in the provided data to inform the company's current strategic direction or operational developments.

Free cash flow surged 24.5% year-over-year to HKD 57.4 million, demonstrating strong operational cash generation capabilities.

Revenue grew 12.4% year-over-year to HKD 748.5 million, indicating successful top-line expansion despite margin pressures.

Long-term debt decreased slightly to HKD 161.6 million in FY0, suggesting a modest improvement in leverage management.

Dilution risk is assessed as low, providing some protection for existing shareholders against equity value erosion.

Total assets grew 6.7% year-over-year to HKD 1.1 billion, reflecting continued balance sheet expansion and scale.

Revenue CAGR was a negligible 0.7% over four years, showing a lack of meaningful long-term growth trajectory.

Equity CAGR was negative 0.5% over five years, suggesting stagnant or declining shareholder value creation over time.

Revenue HK$726.9M, −2,9% YoY; Operating income +0,2% YoY.

• ▍Revenue HK$726.9M, −2,9% YoY
• ▍Operating income +0,2% YoY
• ▍Net income −22,6% YoY
• ▍Free cash flow +71,7% YoY
• ▍Net margin 4.3%

Revenue HK$727.2M, +9,2% YoY; Operating income −18,8% YoY.

• ▍Revenue HK$727.2M, +9,2% YoY
• ▍Operating income −18,8% YoY
• ▍Net income −16,2% YoY
• ▍Free cash flow −41,0% YoY
• ▍Net margin 8.3%